Given the role of Th22 cells and IL-22 in maintaining the mucosal barrier, it can be inferred that pathways enhancing Th22 or IL-22 levels may hold therapeutic potential, particularly for IBD. The gene discussed is IL22; the disease is inflammatory bowel disease.